Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), has today announced to the markets the publication of a new trial showing excellent results from using ODM in thoracic surgery.
The results of the randomised controlled trial of 100 patients undergoing lung surgery at the University of Freiburg in Germany have been published online by the British Journal of Anaesthesia. Vascular fluids and vaso-active drugs were administered during surgery in accordance with Enhanced Recovery After Surgery (‘ERAS’) Society recommended protocols.
Nine fewer ODM patients (six v 15) suffered post-operative pulmonary complications and ODM patients had a two day shorter stay in hospital (nine v 11 days). This is the first published randomised controlled trial studying ODM use during thoracic surgery.
Reference: Kaufmann et al. Oesophageal Doppler guided goal-directed haemodynamic therapy in thoracic surgery – a single centre randomized parallel-arm trial. BJA: 118 (6): 852-61 (2017).
Ewan Phillips, Deltex Medical Group plc Chief Executive, commented: “This is excellent news for large numbers of patients undergoing lung resection with one in five of them avoiding a dangerous, life shortening, complication. The trial allows us to target thoracic surgery on top of those other specific types of surgery where the value of ODM has previously been demonstrated.
“In the NHS in England there are around 40,000 patients a year undergoing higher risk thoracic procedures with a risk of post-operative death within 30 days of 1% or higher and very few of these have fluids or vaso-active drugs administered with the aid of ODM.”
